CMPX Compass Therapeutics, Inc. Insider Trading

Chief Accounting Officer Neil Lerner buys 15,000 shares at $1.89, his second open-market purchase in 36 months, as stock trades sharply below 52-week highs.

Neil Lerner, Chief Accounting Officer of Compass Therapeutics, purchased 15,000 shares on the open market at $1.89, marking his second open-market purchase within the past 36 months. The stock is currently trading well below its 52-week high, having fallen sharply over the recent period and approaching its 52-week low. His prior open-market purchase at this company, made roughly a year ago, was followed by significant gains over the subsequent quarter, demonstrating well-timed entry into the stock. This repeat buying at substantially lower prices mirrors the pattern of his previous purchase—entering when the stock is under pressure. The company is not currently profitable and carries substantial operating losses, making this a purchase into fundamentals weakness rather than strength. Lerner's return to the open market after his prior successful buy suggests he views current price levels as an opportunity, though the deteriorated financial position since his last purchase makes this a contrarian move into an earlier-stage therapeutic biotech in distress.

General Counsel Anderman repurchases CMPX shares at 15-month lows; repeat buyer with perfect timing on prior trade.

Jonathan Anderman, the company's General Counsel, is making his second open-market purchase of CMPX shares in 36 months, adding materially to his stake at a point when the stock trades well below its 52-week high. The timing is noteworthy: his prior open-market purchase last year generated strong gains within months, demonstrating he has executed well-timed purchases at this company before. This current buy occurs as the stock sits near its 52-week low following a sharp decline, positioning the trade as a bet on recovery from deeply depressed prices. However, the company remains unprofitable with zero revenue, operating at a significant cash burn, which means Anderman is buying into fundamental weakness—not filling a cyclical dip in an otherwise healthy business. His willingness to deploy capital despite these deteriorating fundamentals is the core signal: either he has visibility into a near-term inflection point that is not yet reflected in the financials, or he is accumulating on weakness believing long-term value exists at these prices.